chloral hydrate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	586	302-17-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: chloral hydrate chloraldurat nycoton phaldrone trichloroacetaldehyde hydrate	A hypnotic and sedative used in the treatment of INSOMNIA. Molecular weight: 165.39 Formula: C2H3Cl3O2 CLOGP: 0.72 LIPINSKI: 0 HAC: 2 HDO: 2 TPSA: 40.46 ALOGS: -0.58 ROTB: 1

Molecule

Description

Molfile Inchi Smiles

Synonyms:

chloral hydrate
chloraldurat
nycoton
phaldrone
trichloroacetaldehyde hydrate

A hypnotic and sedative used in the treatment of INSOMNIA.

Molecular weight: 165.39
Formula: C2H3Cl3O2
CLOGP: 0.72
LIPINSKI: 0
HAC: 2
HDO: 2
TPSA: 40.46
ALOGS: -0.58
ROTB: 1

Drug dosage:

Dose	Unit	Route
1	g	O
1	g	R

ADMET properties:

Show entries

Search:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	86.37 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
S (Water solubility)	8300 mg/mL	Benet LZ, Broccatelli F, Oprea TI
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI

Showing 1 to 3 of 3 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1840	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypomania	570.42	150.63	109	2096	6221	63480596
Jaundice cholestatic	548.45	150.63	108	2097	7216	63479601
Schizophrenia	527.03	150.63	110	2095	9842	63476975
Psychotic disorder	408.59	150.63	107	2098	25605	63461212
Hepatotoxicity	378.86	150.63	109	2096	36932	63449885
Blood bilirubin increased	378.58	150.63	109	2096	37031	63449786
Cholelithiasis	364.84	150.63	110	2095	43815	63443002
Hepatic enzyme increased	202.06	150.63	110	2095	202218	63284599
Asthma-chronic obstructive pulmonary disease overlap syndrome	194.55	150.63	37	2168	2024	63484793
Total lung capacity increased	190.34	150.63	37	2168	2273	63484544

Showing 1 to 10 of 11 entries

Previous1 2Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sedation complication	80.02	54.10	15	517	1762	34954637
Respiratory failure	65.37	54.10	32	500	108540	34847859
Hypoventilation	64.59	54.10	14	518	3400	34952999

Showing 1 to 3 of 3 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypomania	546.29	73.29	108	2622	7436	79734222
Jaundice cholestatic	502.93	73.29	108	2622	11176	79730482
Schizophrenia	479.94	73.29	110	2620	15330	79726328
Psychotic disorder	367.90	73.29	109	2621	41293	79700365
Cholelithiasis	346.20	73.29	110	2620	52554	79689104
Hepatotoxicity	344.76	73.29	109	2621	51243	79690415
Blood bilirubin increased	313.60	73.29	108	2622	66124	79675534
Hepatic enzyme increased	216.61	73.29	111	2619	182499	79559159
Total lung capacity increased	191.01	73.29	37	2693	2261	79739397
Asthma-chronic obstructive pulmonary disease overlap syndrome	178.54	73.29	37	2693	3184	79738474

Showing 1 to 10 of 19 entries

Previous1 2Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	N05CC01	NERVOUS SYSTEM PSYCHOLEPTICS HYPNOTICS AND SEDATIVES Aldehydes and derivatives
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:35717	hypnotics
CHEBI has role	CHEBI:38869	general anaesthetic
CHEBI has role	CHEBI:75771	Mus musculus metabolites
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D006993	Hypnotics and Sedatives

Showing 1 to 8 of 8 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
General anesthesia	indication	50697003
Insomnia	indication	193462001
Sedation	off-label use	72641008
Proctitis	contraindication	3951002	DOID:3127
Gastritis	contraindication	4556007	DOID:4029
Peptic ulcer	contraindication	13200003	DOID:750
Esophagitis	contraindication	16761005	DOID:11963
Inflammatory bowel disease	contraindication	24526004	DOID:0050589
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004

Showing 1 to 10 of 13 entries

Previous1 2Next

🐶 Veterinary Drug Use

Show entries

Search:

Species	Use	Relation
Cattle	General anesthesia	Indication
Cattle	Sedation	Indication
Horses	General anesthesia	Indication
Horses	Sedation	Indication

Showing 1 to 4 of 4 entries

Previous1Next

🐶 Veterinary products

Product	Applicant	Ingredients
Chloropent	Zoetis Inc.	3

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.9	acidic
pKa2	13.19	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

Show entries

Search:

ID	Source
001427	NDDF
2344	RXNORM
2707	PUBCHEM_CID
273948005	SNOMEDCT_US
28748001	SNOMEDCT_US
3870	MMSL
4017726	VUID
4017726	VANDF
418M5916WG	UNII
4404	MMSL

Showing 1 to 10 of 18 entries

Previous1 2Next

Pharmaceutical products:

None